The risk for major bleeding associated with prior minor bleeding during treatment with vitamin K antagonists appeared linked to fixed, still unknown, risk factors, according to study results. Previous studies have shown that patients on vitamin K antagonists (VKAs) who experience minor bleeding are at increased risk for major bleeding; however, when researchers adjust for known risk factors — such as overanticoagulation, diabetes, diuretic use and malignancy — the increased risk persisted.
